Health
Phase 3 Program Investigating COMP360 Psilocybin for Treatment-Resistant Depression: Breaking Poster Data From the 2026 ASCP Annual Meeting – Psychiatric Times
Phase 3 Program Investigating COMP360 Psilocybin for Treatment-Resistant Depression: Breaking Poster Data From the 2026 ASCP Annual Meeting Psychiatric TimesPsilocybin research is no longer just for hard-to-treat cases — a new…




